Mouse Monoclonal ABCG8 Antibody Announced by Novus Biologicals
Littleton, CO, August 03, 2011 --(PR.com)-- Novus Biologicals announced today a new mouse monoclonal ABCG8 antibody.
ABCG8 is an ATP binding cassette family member which acts to exclude non-cholesterol sterol entry to the intestine, to promote excretion of cholesterol and sterols into bile, and to facilitate transport of sterols back into the intestinal lumen. Novus’ new ABCG8 antibody (Catalog Number NBP1-71706) is useful for highly specific Westerm blot, immunoprecipitation, and immunofluorescence staining on paraffin-embedded mouse samples.
Normal digestion is partially facilitated by the function of ABCG8 and its counterpart ABCG5, which together form a heterodimer which transports cholesterol out of the liver and into bile. Subsequently, cholesterol is eliminated from the bodies of healthy individuals. However, in cases of insulin resistance, this functionality is impaired, and digestion does not result in complete elimination of harmful cholesterol. Unsurprisingly, mutations in ABCG8 can lead to gallstone disease, biliary cancer, hypercholesterolemia and atherosclerosis. In studies related to diabetes, heart disease, and digestive cancers, ABCG8 is commonly assessed for normal expression, function and interaction with ABCG5.
The ABCG8 antibodies are highly characterized and extremely useful tools for cholesterol and lipid metabolism research. We also offer ABCG8 RNAi and various tissue slides and lysates for use as controls.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
###
ABCG8 is an ATP binding cassette family member which acts to exclude non-cholesterol sterol entry to the intestine, to promote excretion of cholesterol and sterols into bile, and to facilitate transport of sterols back into the intestinal lumen. Novus’ new ABCG8 antibody (Catalog Number NBP1-71706) is useful for highly specific Westerm blot, immunoprecipitation, and immunofluorescence staining on paraffin-embedded mouse samples.
Normal digestion is partially facilitated by the function of ABCG8 and its counterpart ABCG5, which together form a heterodimer which transports cholesterol out of the liver and into bile. Subsequently, cholesterol is eliminated from the bodies of healthy individuals. However, in cases of insulin resistance, this functionality is impaired, and digestion does not result in complete elimination of harmful cholesterol. Unsurprisingly, mutations in ABCG8 can lead to gallstone disease, biliary cancer, hypercholesterolemia and atherosclerosis. In studies related to diabetes, heart disease, and digestive cancers, ABCG8 is commonly assessed for normal expression, function and interaction with ABCG5.
The ABCG8 antibodies are highly characterized and extremely useful tools for cholesterol and lipid metabolism research. We also offer ABCG8 RNAi and various tissue slides and lysates for use as controls.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
###
Contact
Novus Biologicals
Amy Chamberlain-Torres
303-730-1950
www.NovusBio.com
Amy Chamberlain-Torres
303-730-1950
www.NovusBio.com
Contact
Categories